TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03804645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Each subject will receive single dose of AZD9977 capsule under fasting condition in Part A. If the formulation chosen for Part B, each subject will receive one dose under fed condition and another dose under fasted condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Each subject will receive single dose of AZD9977 capsule under fasting condition in Part A. If the formulation chosen for Part B, each subject will receive one dose under fed condition and another dose under fasted condition.
Study: NCT03777436

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral
Study: NCT03996005

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Tissue
Description: Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Tissue
Study: NCT02798380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTS-519 Insert
Description: Maximum feasible dose of HTS-519 Insert per diseased nail
Study: NCT04089904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Injection
Description: Patients will receive 3 cycles of pembrolizumab at 200mg intravenously on day 1 of a 3 week cycle. After 3 cycles the patients will undergo surgery
Study: NCT01903330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ERC1671
Description: Given intradermally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: Given intradermally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given PO. Drug class: Alkylating Agent; Antineoplastic Agent; Nitrogen Mustard.
Study: NCT03804645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Each subject will receive single dose of AZD9977 capsule under fasting condition in Part A. If the formulation chosen for Part B, each subject will receive one dose under fed condition and another dose under fasted condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Each subject will receive single dose of AZD9977 capsule under fasting condition in Part A. If the formulation chosen for Part B, each subject will receive one dose under fed condition and another dose under fasted condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Each subject will receive single dose of AZD9977 capsule under fasting condition in Part A. If the formulation chosen for Part B, each subject will receive one dose under fed condition and another dose under fasted condition.
Study: NCT01903330

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral Control (Sucrose pill)
Description: Given PO

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Injectable control (Sodium Chloride Injection United States Pharmacopeia (USP) (0.9%))
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab/Bevacizumab Biosimilar
Description: Given IV. Drug class: Immunological Agent; Monoclonal Antibody.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bevacizumab/Bevacizumab Biosimilar
Description: Given IV. Drug class: Immunological Agent; Monoclonal Antibody.
Study: NCT01343680

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: 5ml 10 units/ml IV heparin 3 times per week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: 10ml normal saline IV weekly
Study: NCT02882581

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 11C-metformin
Description: 400MBq of 11C-metformin is injected in the cubital vein. The participant is then scanned for 120 min using Position Emission Tomography.
Study: NCT04008719

Intervention type: OTHER
Group type: OTHER
Intervention: Thymic history
Description: This interview concerns mainly the nature of the previous psychiatric and psychological care

Intervention type: OTHER
Group type: OTHER
Intervention: Evaluation of the psychiatric disorders
Description: Mini International Neuropsychiatric Interview for the positive diagnosis of depression - under the MINI score of depression.

Intervention type: OTHER
Group type: OTHER
Intervention: Cognitive evaluation
Description: They will be held consecutively to the patient's bedside interview on the same day. Some tests will be computerized, others will be in paper form.
Study: NCT01557374

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab, Abatacept
Description: Tocilizumab: Roactemra 4-8 mg/kg/month and 162 mg/week Abatacept: Orencia 500-1000 mg/month and 125 mg/week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decrease Tocilizumab, Abatacept
Description: The decrease pattern is established on 4 consecutive stages :~IV Abatacept (500-1000 mg/month) and Tocilizumab(4-8 mg/kg/month):~Stage 0 : Perfusion /30 days Stage 1 :Perfusion/45 days Stage 2 :Perfusion/60 days Stage 3 :Perfusion/90 days Stage 4 :Stop~SC Abatacept (125 mg/week) and Tocilizumab (162 mg/week):~Stage 0 :Injection/7 days Stage 1 :Injection/10 days Stage 2 :Injection/14 days Stage 3 :Injection/21 days Stage 4 :Stop~* If DAS 28 ≤ 2,6 (remission DAS persistent) on trimestrial visit: transfer to next stage for 3 months before next evaluation.~* If DAS 28 \> 2,6 et ≤ 3,2 (weak activity) : maintain ongoing stage~* If DAS 28 \> 3,2 : return to previous stage, (relapse according to European expert consensus)~In the case of relapse while the patient is in stage 0, the therapy modification is left to the investigator's free will, but the patient will be followed till the end of the study.
Study: NCT04026074

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo salve
Description: Skin protection salve (placebo salve) application on the body part where the regional anaesthesia will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo salve
Description: Skin protection salve (placebo salve) application on the body part where the regional anaesthesia will be administered
Study: NCT00348283

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: adalimumab
Description: At Baseline (Week 0), subjects received an OL dose of 160 mg adalimumab SC followed by an OL dose of 80 mg adalimumab SC at Week 2 (induction dose). At Week 4, subjects were randomized to either adalimumab 40 mg SC eow or placebo SC eow. Adalimumab 40 mg eow dosing through blinded portion of study, which continued through Week 52. While all subjects began blinded study drug (placebo or adalimumab), subjects could have switched to an OL dose of adalimumab upon disease flare or non-response at or after Week 8.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: At Baseline (Week 0), subjects received an OL dose of 160 mg adalimumab SC followed by an OL dose of 80 mg adalimumab SC at Week 2 (induction dose). At Week 4, subjects were randomized to either adalimumab 40 mg SC eow or placebo SC eow. Placebo SC eow dosing through blinded portion of study, which continued through Week 52. While all subjects began blinded study drug (placebo or adalimumab), subjects could have switched to an OL dose of adalimumab upon disease flare or non-response at or after Week 8.
Study: NCT03804645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Each subject will receive single dose of AZD9977 HDL capsule under fasting condition in Part A. If the formulation chosen for Part B, each subject will receive one dose under fed condition and another dose under fasted condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Each subject will receive single dose of AZD9977 HDL capsule under fasting condition in Part A. If the formulation chosen for Part B, each subject will receive one dose under fed condition and another dose under fasted condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Each subject will receive single dose of AZD9977 HDL capsule under fasting condition in Part A. If the formulation chosen for Part B, each subject will receive one dose under fed condition and another dose under fasted condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Each subject will receive single dose of AZD9977 HDL capsule under fasting condition in Part A. If the formulation chosen for Part B, each subject will receive one dose under fed condition and another dose under fasted condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Each subject will receive single dose of AZD9977 HDL capsule under fasting condition in Part A. If the formulation chosen for Part B, each subject will receive one dose under fed condition and another dose under fasted condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: Each subject will receive single dose of AZD9977 ODL capsule under fasting condition in Part A. If the formulation chosen for Part B, each subject will receive one dose under fed condition and other dose under fasted condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: Each subject will receive single dose of AZD9977 ODL capsule under fasting condition in Part A. If the formulation chosen for Part B, each subject will receive one dose under fed condition and other dose under fasted condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: Each subject will receive single dose of AZD9977 ODL capsule under fasting condition in Part A. If the formulation chosen for Part B, each subject will receive one dose under fed condition and other dose under fasted condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: Each subject will receive single dose of AZD9977 ODL capsule under fasting condition in Part A. If the formulation chosen for Part B, each subject will receive one dose under fed condition and other dose under fasted condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: Each subject will receive single dose of AZD9977 ODL capsule under fasting condition in Part A. If the formulation chosen for Part B, each subject will receive one dose under fed condition and other dose under fasted condition.
Study: NCT00348283

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: adalimumab
Description: At Baseline (Week 0), subjects received an OL dose of 160 mg adalimumab SC followed by an OL dose of 80 mg adalimumab SC at Week 2 (induction dose). At Week 4, subjects were randomized to either adalimumab 40 mg SC eow or placebo SC eow. Adalimumab or placebo SC eow dosing through blinded portion of study, which continued through Week 52. While all subjects began blinded study drug (placebo or adalimumab), subjects could have switched to an OL dose of adalimumab upon disease flare or non-response at or after Week 8. In the Open-Label arm, interventions were either adalimumab 40 mg SC eow or adalimumab 40 mg SC weekly. There was no placebo intervention post Week 52.
Study: NCT00515281

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: inhaled nitric oxide
Description: The amount of gas will be carefully controlled and adjusted to the level that best improves the function of subject's lungs. The subject will remain on inhaled nitric oxide until he/she reaches 33 weeks of gestation if assigned to the treatment arm, or until the 8th day of the study if he/she is assigned to the control arm.
Study: NCT03804645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D
Description: Each subject will receive single dose of AZD9977 tablet under fasting condition in Part A. If the formulation chosen for Part B, each subject will receive one dose under fed condition and another dose under fasted condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D
Description: Each subject will receive single dose of AZD9977 tablet under fasting condition in Part A. If the formulation chosen for Part B, each subject will receive one dose under fed condition and another dose under fasted condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D
Description: Each subject will receive single dose of AZD9977 tablet under fasting condition in Part A. If the formulation chosen for Part B, each subject will receive one dose under fed condition and another dose under fasted condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D
Description: Each subject will receive single dose of AZD9977 tablet under fasting condition in Part A. If the formulation chosen for Part B, each subject will receive one dose under fed condition and another dose under fasted condition.
Study: NCT00515281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled nitric oxide
Description: The amount of gas will be carefully controlled and adjusted to the level that best improves the function of subject's lungs. The subject will remain on inhaled nitric oxide until he/she reaches 33 weeks of gestation if assigned to the treatment arm, or until the 8th day of the study if he/she is assigned to the control arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxygen
Description: The amount of gas will be carefully controlled and adjusted to the level that best improves the function of the subject's lungs. Subjects in the control arm of the study will receive oxygen beginning on the 8th day of the study until he/she reaches 33 weeks of gestation.
Study: NCT04281875

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIRAF Detection Technology
Description: Near Infrared Autofluorescence (NIRAF) detection technology or 'PTeye' consists of a disposable fiber-optic probe that emits non-ionizing radiation from a NIR 785 nm laser source, and also transmits the resulting tissue NIRAF to a photo detector. The 785 nm laser source emits a maximum power of 20 mW. The device is FDA cleared for clinical use in general surgeries and dermatological use (Class 2 device).~After surgeon identifies a potential parathyroid gland in the surgical field, the surgeon places the fiber-optic probe of PTeye on suspect tissue and presses the device foot-pedal to activate tissue NIRAF measurement. Auditory beep at high frequency with a Detection Ratio \> 1.2 is interpreted by device as the suspect tissue being positive for parathyroid.
Study: NCT02481349

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Undergo standard of care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Receive DVD for home practice

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Complete couple-based Hatha yoga program
Study: NCT01765439

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VSL#3 (Original De Simone formulation)
Description: Study subjects will receive two sachets of VSL#3 probiotic (ie 2x900 billions of live bacteria) per day (one in the morning, one in the evening). The intervention period will be 6 weeks (plus or minus 5 days).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VSL#3 (Original De Simone formulation)
Description: Study subjects will receive two sachets of VSL#3 probiotic (ie 2x900 billions of live bacteria) per day (one in the morning, one in the evening). The intervention period will be 6 weeks (plus or minus 5 days).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VSL#3 (Original De Simone formulation)
Description: Study subjects will receive two sachets of VSL#3 probiotic (ie 2x900 billions of live bacteria) per day (one in the morning, one in the evening). The intervention period will be 6 weeks (plus or minus 5 days).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VSL#3 (Original De Simone formulation)
Description: Study subjects will receive two sachets of VSL#3 probiotic (ie 2x900 billions of live bacteria) per day (one in the morning, one in the evening). The intervention period will be 6 weeks (plus or minus 5 days).
Study: NCT03443752

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shotokan-Karate
Description: The Shotokan-Karate training program will be ran over a period of 12 weeks. Classes will be conducted 3 times per week at the Movement Disorders Rehabilitation Centre in Waterloo, Ontario. The program will be conducted by a trained professional (principal investigator), and there will be volunteers who ensure the safety and well-being of participants.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tai-Chi
Description: The Tai-Chi training program will be ran over a period of 12 weeks. Classes will be conducted 3 times per week at the Movement Disorders Rehabilitation Centre in Waterloo, Ontario. The program will be conducted by a trained professional (principal investigator), and there will be volunteers who ensure the safety and well-being of participants.
Study: NCT01145547

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dexcom Seven® Plus Continuous Glucose Monitoring sensor
Description: A Dexcom Seven® Plus Continuous Glucose Monitoring sensor was inserted subcutaneously into each subject.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dexcom Seven® Plus Continuous Glucose Monitoring sensor
Description: A Dexcom Seven® Plus Continuous Glucose Monitoring sensor was inserted subcutaneously into each subject.
Study: NCT01018576

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping
Description: Infants will be covered with plastic and placed on a chemical warmer at delivery and then clamping of the umbilical cord will be delayed for 30-60 seconds.
Study: NCT01770314

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Participants will be given instructions via email to review eleven online lessons about opioid medication safety. Instructions will suggest that participants view one lesson per day for eleven consecutive days. Each educational lesson focuses on one or two aspects of medication safety, including how to safely store medication, and the importance of taking medication exactly as prescribed.
Study: NCT03093597

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: virgin coconut oil
Description: One of the four locations (right proximal forearm, right distal forearm, left proximal forearm, left distal forearm) on the forearm will be selected to receive virgin coconut oil application twice daily for 2 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: virgin jojoba oil
Description: One of the four locations (right proximal forearm, right distal forearm, left proximal forearm, left distal forearm) on the forearm will be selected to receive virgin jojoba oil application twice daily for 2 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: virgin almond oil
Description: One of the four locations (right proximal forearm, right distal forearm, left proximal forearm, left distal forearm) on the forearm will be selected to receive virgin almond oil application twice daily for 2 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: white petrolatum ointment
Description: One of the four locations (right proximal forearm, right distal forearm, left proximal forearm, left distal forearm) on the forearm will be selected to receive white petrolatum ointment application twice daily for 2 weeks.
Study: NCT00688051

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: My Life with CF game
Description: Play the game My Life with CF
Study: NCT02145195

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (cholecalciferol)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (cholecalciferol)
Study: NCT04140422

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperosmolar eye drops
Description: Application of one preservative-free hyperosmolar eye drop, when waking up and one eye drop 30 min later to one eye by the investigators

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Application of one preservative-free lubricating eye drop, when waking up and one eye drop 30 min later to the fellow eye by the investigators
Study: NCT03804645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D
Description: Each subject will receive single dose of AZD9977 tablet under fasting condition in Part A. If the formulation chosen for Part B, each subject will receive one dose under fed condition and another dose under fasted condition.
Study: NCT03427957

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Endometrial biopsy with the new hysteroscopic grasper with knurled terminal end and cutting jaws
Description: Hysteroscopic endometrial biopsy performed through the new grasper with knurled terminal end and cutting jaws.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Endometrial biopsy with the hysteroscopic spoon grasper
Description: Hysteroscopic endometrial biopsy performed through the spoon grasper.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Endometrial biopsy with the hysteroscopic alligator grasper
Description: Hysteroscopic endometrial biopsy performed through the alligator grasper.
Study: NCT00796237

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole body vibration therapy
Description: In their regular physiotherapy sessions, the subjects in the experimental group will receive WBV (20-240Hz, 10-minute sessions, 1 session per day, 5 sessions per week). The vibration loading will be carried out using the Fit-Vibe System (Germany), which is a vibration platform that is capable of generating vertical vibration.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standing on the vibration platform but no vibration will be applied
Description: The subjects in this group will perform the same exercises on the vibration platform as in the experimental group for the same duration, but no vibration will be given.
Study: NCT02231320

Intervention type: DRUG
Intervention: Berodual® Respimat® - inhaler
Study: NCT04784481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: Experimental Group received Ivermectin orally 4 tablets of 6 mg = 24 mg every 7 days for 4 weeks.
Study: NCT02056899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Study: NCT00279942

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Soy
Description: Drink a shake (vanilla and chocolate taste) once a day for 6 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drink a shake (vanilla and chocolate taste) once a day for 6 weeks.